NCT01020838View on ClinicalTrials.gov

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2013

Conditions
Alzheimer Disease
Interventions
DRUG

Florbetaben (BAY94-9172)

Single intravenous injection 1-5ml, 300 MBq (+/- 20%)

Trial Locations (19)

3084

Heidelberg

19104

Philadelphia

33616

Tampa

52425

Jülich

59037

Lille

67091

Strasbourg

75390

Dallas

77030

Houston

78229

San Antonio

85351

Sun City

94305

Stanford

07666

Teaneck

04103

Leipzig

440-0045

Toyohashi

441-8021

Toyohashi

441-8124

Toyohashi

372-0006

Isesaki

432-8580

Hamamatsu

173-0015

Itabashi-ku

Sponsors
All Listed Sponsors
lead

Life Molecular Imaging SA

INDUSTRY

NCT01020838 - Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology | Biotech Hunter | Biotech Hunter